Table 2.
Treatment, n (%) | Black patients (n = 87) | White patients (n = 582) |
---|---|---|
Neoadjuvant systemic therapy | 22 (25.3) | 118 (20.3) |
Adjuvant systemic therapy | 58 (66.7) | 439 (75.4) |
Neoadjuvant/adjuvant trastuzumab | 6 (6.9) | 44 (7.6) |
Patients diagnosed in stages 0–III only or with missing clinical cancer stage